Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Avelumab in gastric cancer.

Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N.

Immunotherapy. 2019 May 6. doi: 10.2217/imt-2019-0011. [Epub ahead of print]

PMID:
31060469
2.

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.

Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T.

Cells. 2019 Apr 6;8(4). pii: E321. doi: 10.3390/cells8040321. Review.

3.

Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?

Roviello G, Sohbani N, Petrioli R, Rodriquenz MG.

Invest New Drugs. 2019 Mar 16. doi: 10.1007/s10637-019-00760-0. [Epub ahead of print] Review.

PMID:
30879152
4.

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.

Roviello G, Generali D.

Clin Genitourin Cancer. 2019 Feb 6. pii: S1558-7673(18)30797-3. doi: 10.1016/j.clgc.2019.01.020. [Epub ahead of print] No abstract available.

PMID:
30827924
5.

Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue.

Roviello G, Generali D, Ianza A.

Immunotherapy. 2019 Apr;11(5):365-368. doi: 10.2217/imt-2018-0204. No abstract available.

6.

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.

Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M.

Invest New Drugs. 2019 Jan 28. doi: 10.1007/s10637-019-00725-3. [Epub ahead of print]

PMID:
30687871
7.

The promising role of monoclonal antibodies for gastric cancer treatment.

Afshari F, Soleyman-Jahi S, Keshavarz-Fathi M, Roviello G, Rezaei N.

Immunotherapy. 2019 Mar;11(4):347-364. doi: 10.2217/imt-2018-0093.

PMID:
30678552
8.

Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy.

Roviello G, Corona SP, Aieta M, Roudi R.

Cancer Biother Radiopharm. 2019 Apr;34(3):141-146. doi: 10.1089/cbr.2018.2702. Epub 2019 Jan 8.

PMID:
30620216
9.

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223.

Roviello G, Gallicchio R, Bozza G, Rodriquenz MG, Aieta M, Storto G.

Onco Targets Ther. 2018 Dec 17;12:9-13. doi: 10.2147/OTT.S174206. eCollection 2019.

10.

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.

Roviello G, Petrioli R, Bonetta A, Conca R, Rodriquenz MG, Aieta M.

Invest New Drugs. 2018 Dec;36(6):1110-1115. doi: 10.1007/s10637-018-0685-7. Epub 2018 Oct 22.

PMID:
30345466
11.

Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer.

Roviello G, Generali D.

Lancet Oncol. 2018 Oct;19(10):1270-1272. doi: 10.1016/S1470-2045(18)30512-6. Epub 2018 Sep 11. No abstract available.

PMID:
30217673
12.

Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?

Roviello G, Imperatori M, Aieta M, Sollitto F, Landriscina M.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2114-S2118. doi: 10.21037/jtd.2018.06.114. No abstract available.

13.

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience.

Roviello G, Generali D, Aieta M, Bonetta A.

Rep Pract Oncol Radiother. 2018 Jul-Aug;23(4):298-299. doi: 10.1016/j.rpor.2018.06.001. Epub 2018 Jul 17.

PMID:
30100818
14.

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G.

Invest New Drugs. 2018 Dec;36(6):1133-1137. doi: 10.1007/s10637-018-0653-2. Epub 2018 Aug 7. Review.

PMID:
30083960
15.

Familial aggregation of gastric cancer with microsatellite instability.

Polom K, Marrelli D, Voglino C, Roviello G, De Franco L, Vindigni C, Generali D, Roviello F.

Acta Chir Belg. 2018 Oct;118(5):287-293. doi: 10.1080/00015458.2017.1379789. Epub 2018 Aug 3.

PMID:
30071769
16.

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.

Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D.

Cells. 2018 Jul 15;7(7). pii: E76. doi: 10.3390/cells7070076. Review.

17.

Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis.

Pieraccini M, Guerrini S, Laiolo E, Puliti A, Roviello G, Misuraca L, Spargi G, Limbruno U, Breggia M, Grechi M.

Cardiovasc Intervent Radiol. 2018 Dec;41(12):1840-1848. doi: 10.1007/s00270-018-2011-3. Epub 2018 Jul 6.

PMID:
29980817
18.

PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.

Polom K, Marrelli D, Roviello G, Pascale V, Voglino C, Vindigni C, Generali D, Roviello F.

Adv Clin Exp Med. 2018 Jul;27(7):963-969. doi: 10.17219/acem/70795.

19.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M.

Oncotarget. 2018 Apr 27;9(32):22332-22339. doi: 10.18632/oncotarget.24900. eCollection 2018 Apr 27.

20.

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M.

Medicine (Baltimore). 2018 May;97(20):e10745. doi: 10.1097/MD.0000000000010745.

Supplemental Content

Loading ...
Support Center